1. Lifecore Biomedical to be added to Nasdaq Biotech Index effective December 22, 2025. 2. Inclusion indicates Lifecore meets Nasdaq's market capitalization and trading volume requirements. 3. Lifecore specializes in manufacturing sterile injectable pharmaceutical products. 4. The Nasdaq Biotech Index tracks performance of selected biotech and pharmaceutical stocks. 5. Lifecore's expertise spans over 40 years in biopharmaceutical manufacturing.
FAQ
Why Bullish?
Inclusion in the Nasdaq Biotech Index typically raises visibility and investor interest. Historical instances show stocks often appreciate post-inclusion, reflecting enhanced credibility.
How important is it?
The announcement indicates a significant corporate development likely to attract institutional and retail investors, enhancing liquidity and price stability.
Why Short Term?
The immediate effect of higher visibility from index inclusion is likely to influence stock price quickly. Such events usually result in short-term buying pressure leading to price increases.
Lifecore Biomedical to Join Nasdaq Biotech Index
CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR), a leading contract development and manufacturing organization (CDMO), has announced its upcoming inclusion in the Nasdaq Biotech Index (NASDAQ: NBI). This significant milestone is part of the annual reconstitution of the Nasdaq indexes and will take effect prior to market open on Monday, December 22, 2025.
Inclusion in the Nasdaq Biotech Index
Lifecore Biomedical's addition to the Nasdaq Biotech Index underscores its position within the biotechnology and pharmaceutical sectors. The Nasdaq Biotechnology Index is designed to track the performance of Nasdaq-listed securities classified under these industries according to the Industry Classification Benchmark (ICB).
This index operates under a modified capitalization-weighted methodology, ensuring that companies included must meet strict eligibility criteria. These criteria include:
- Minimum market capitalization
- Average daily trading volume
- Seasoning as a public company
- Other specific criteria set by Nasdaq
Constituents are selected annually in December, highlighting the competitive landscape of the biotechnology market.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (NASDAQ: LFCR) specializes as a fully integrated contract development and manufacturing organization (CDMO). The company is noted for its advanced capabilities in the development, fill, and finish of sterile injectable pharmaceutical products, which are available in various formats such as syringes, vials, and cartridges, including complex formulations.
With more than 40 years of experience, Lifecore is a premier manufacturer of injectable-grade hyaluronic acid, providing essential expertise as a partner to both global and emerging biopharmaceutical and biotechnology companies. Lifecore's commitment to innovation supports multiple therapeutic categories, helping to bring groundbreaking products to market.
Looking Ahead
This inclusion in the Nasdaq Biotech Index is a positive development for Lifecore Biomedical, as it reflects the company's growth and significance within the biotech sector. Investors and stakeholders can expect Lifecore to continue its trajectory of innovation and excellence in the pharmaceutical manufacturing space.
For further information, visit Lifecore’s official website at www.lifecore.com.